# US 2026/0061043 A1 · Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061043 A1
- Document ID: US20260061043A1
- Status: Published application
- Kind: A1
- Application number: 19/021,372
- Filed: 2025-01-15
- Published: 2026-03-05
- Earliest claimed: 2019-04-10
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Annaliesa Sybil Anderson; Isis Kanevsky; Farid Latif Khan; Charles Harold Jones; John Michael McLaughlin
- Web page: https://patentgrep.com/patent/US20260061043A1

## CPC

- A61K 39/092: {Streptococcus}
- A61K 39/116: Polyvalent bacterial antigens
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 31/04: Antibacterial agents
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/70: {Multivalent vaccine}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

## Claims

### Claim 1

An immunogenic composition comprising at least one glycoconjugate comprising a Streptococcus pneumoniae (S. pneumoniae) capsular polysaccharide conjugated to a carrier protein, wherein said capsular polysaccharide is from a S. pneumoniae serotype selected from the group consisting of S. pneumoniae serotypes 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, and 38.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein said composition comprises a glycoconjugate comprising capsular polysaccharide from S. pneumoniae serotype 7C and a glycoconjugate comprising capsular polysaccharide from S. pneumoniae serotype 38.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein the capsular polysaccharide of said glycoconjugates are individually conjugated to CRM197.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, wherein at least one of said serotype 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, or 38 glycoconjugate has a molecular weight of between 1,000 kDa and 20,000 kDa.

### Claim 5 (depends on 1)

The immunogenic composition of claim 1, wherein at least one of said serotype 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, or 38 glycoconjugate comprises less than about 50% of free serotype 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, or 38 capsular polysaccharide compared to the total amount of serotype 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, or 38 capsular polysaccharide.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1, wherein the degree of conjugation of at least one of said serotype 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, or 38 glycoconjugate is between 2 and 15.

### Claim 7 (depends on 1)

The immunogenic composition of claim 1, wherein at least one of said serotype 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, or 38 glycoconjugate is prepared using reductive amination.

### Claim 8 (depends on 1)

The immunogenic composition of claim 1, wherein at least one of said serotype 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, or 38 glycoconjugate has a molecular weight of between 400 kDa and 15,000 kDa.

### Claim 9 (depends on 1)

The immunogenic composition of claim 1, wherein at least one of said serotype 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, or 38 glycoconjugate has a molecular weight of between 1,000 kDa and 8,000 kDa.

### Claim 10 (depends on 1)

The immunogenic composition of claim 1, wherein at least one of said serotype 6C, 7C, 9N, 15A, 15B, 15C, 16F, 17F, 20, 23A, 23B, 31, 34, 35B, 35F, or 38 glycoconjugate is prepared using reductive amination.

### Claim 11 (depends on 1)

The immunogenic composition of claim 1, wherein each dose of said immunogenic composition comprises 0.1 μg to 100 μg of polysaccharide of each serotype.

### Claim 12 (depends on 1)

The immunogenic composition of claim 1, wherein each dose of said immunogenic composition comprises 1.0 μg to 10 μg of polysaccharide of each serotype.

### Claim 13 (depends on 1)

The immunogenic composition of claim 1, wherein each dose of said immunogenic composition comprises about 1.0 μg, about 1.2 μg, about 1.4 μg, about 1.6 μg, about 1.8 μg, 2.0 μg, about 2.2 μg, about 2.4 μg, about 2.6 μg, about 2.8 μg, about 3.0 μg, about 3.2 μg, about 3.4 μg, about 3.6μ, about 3.8μ, about 4.0μ, about 4.2μ, about 4.4μ, about 4.6μ, about 4.8μ, about 5.0 μg, about 5.2 μg, about 5.4 μg, about 5.6 μg, about 5.8 μg or about 6.0 μg of polysaccharide for each serotype glycoconjugate.

### Claim 14 (depends on 1)

The immunogenic composition of claim 1, wherein said immunogenic composition further comprises at least one antigen selected from the group consisting of a diphtheria toxoid (D), a tetanus toxoid (T), a pertussis antigen (P), an acellular pertussis antigen (Pa), a hepatitis B virus (HBV) surface antigen (HBsAg), a hepatitis A virus (HAV) antigen, a conjugated Haemophilus influenzae type b capsular saccharide (Hib), and inactivated poliovirus vaccine (IPV).

### Claim 15 (depends on 1)

The immunogenic composition of claim 1, wherein said immunogenic composition further comprises at least one adjuvant selected from the group consisting of aluminum phosphate, aluminum sulfate or aluminum hydroxide, calcium phosphate, liposomes, an oil-in-water emulsion, MF59 (4.3% w/v squalene, 0.5% w/v polysorbate 80, 0.5% w/v sorbitan trioleate), a water-in-oil emulsion, MONTANIDE™, poly(D,L-lactide-co-glycolide) (PLG) microparticles and poly(D,L-lactide-co-glycolide) (PLG) nanoparticles.

### Claim 16 (depends on 1)

The immunogenic composition of claim 1, wherein said immunogenic composition further comprises a CpG Oligonucleotide.

### Claim 17 (depends on 1)

The immunogenic composition of claim 1, wherein said immunogenic composition has a pH of 5.5 to 7.5.

### Claim 18 (depends on 1)

The immunogenic composition of claim 1, wherein said immunogenic composition is simultaneously, concurrently, concomitantly or sequentially administered with a second immunogenic composition comprising at least one glycoconjugate comprising capsular polysaccharide from a Streptococcus pneumoniae serotype selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F and 33F.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The immunogenic composition of claim 1, further comprising at least 13 glycoconjugates, each comprising capsular polysaccharide from a different S. pneumoniae serotype selected from the group consisting of serotypes 6C, 9N, 15A, 15B, 16F, 20, 23A, 23B, 31, 35B, and 35F.

### Claim 22 (depends on 1)

A method of preventing, treating or ameliorating an infection, disease, or condition associated with S. pneumoniae in a subject, comprising administering to a subject an immunologically effective amount of the immunogenic composition of claim 1.
